<DOC>
	<DOCNO>NCT00542880</DOCNO>
	<brief_summary>This study assess effect two different inhale respiratory medication regard improvement lung function , symptom morning activity .</brief_summary>
	<brief_title>Evaluation Onset Effect Patients With Severe Chronic Obstructive Pulmonary Disease ( COPD ) Treated With Symbicort® Compared Seretide®</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Outpatient , female male age ≥40 year , diagnosis COPD symptoms least 2 year FEV1 ≤50 % predict normal value , prebronchodilator , FEV1/VC &lt; 70 % Prebronchodilator Current respiratory tract disorder COPD History asthma rhinitis Significant unstable cardiovascular disorder</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>COPD</keyword>
	<keyword>Symbicort</keyword>
	<keyword>Seretide</keyword>
</DOC>